RENAL CELL CARCINOMA (RCC)

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery

Retrieved on: 
Thursday, November 18, 2021
Oncology, FDA, Health, Other Health, General Health, Pharmaceutical, KEYNOTE-564, Renal Cell Carcinoma (RCC), Merck’s Early-Stage Cancer Clinical Program, the Merck Access Program for KEYTRYDA, Merck’s Patient Support Program for KEYTRUDA, Merck, KEYNOTE-564, RENAL CELL CARCINOMA (RCC), MERCK’S EARLY-STAGE CANCER CLINICAL PROGRAM, THE MERCK ACCESS PROGRAM FOR KEYTRYDA, MERCK’S PATIENT SUPPORT PROGRAM FOR KEYTRUDA, MERCK

Despite decades of research, limited adjuvant treatment options have been available for earlier-stage renal cell carcinoma patients who are often at risk for recurrence.

Key Points: 
  • Despite decades of research, limited adjuvant treatment options have been available for earlier-stage renal cell carcinoma patients who are often at risk for recurrence.
  • KEYTRUDA is now the first immunotherapy approved for the adjuvant treatment of certain patients with renal cell carcinoma.
  • KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.
  • Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.

FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) as Adjuvant Therapy in Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery

Retrieved on: 
Tuesday, August 10, 2021
Biotechnology, Pharmaceutical, Surgery, Oncology, General Health, Health, FDA, Clinical Trials, KEYNOTE-564, Renal Cell Carcinoma (RCC), Merck, KEYNOTE-564, RENAL CELL CARCINOMA (RCC), MERCK

KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.

Key Points: 
  • KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.
  • KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
  • KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).
  • KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of patients with advanced renal cell carcinoma.

Merck’s KEYTRUDA® (pembrolizumab) Given After Surgery Reduced the Risk of Disease Recurrence or Death by 32% Versus Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC)

Retrieved on: 
Thursday, June 3, 2021
Research, Surgery, Infectious diseases, Clinical trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Clinical medicine, Cancer treatments, Medicine, Breakthrough therapy, Orphan drugs, Antineoplastic drugs, Cancer, Pembrolizumab, Merkel-cell carcinoma, Melanoma, Anaplastic lymphoma kinase, Microsatellite instability, Renal Cell Carcinoma (RCC), Merck, RENAL CELL CARCINOMA (RCC), MERCK

KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.

Key Points: 
  • KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.
  • Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.
  • The safety and effectiveness of KEYTRUDA in pediatric patients with MSI-H central nervous system cancers have not been established.
  • KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).